Moreover, patients with acromegaly treated with either GH-receptor antagonists or somatostatin analogues represent a peculiar setting that need to be studied in depth to define safety and efficacy of both drug classes and their interaction with the GH/IGF-1 axis. This evidence concerns the gene IGF1 and acromegaly.